BD (Becton, Dickinson and Company)

BD (Becton, Dickinson and Company)
Name	BD (Becton, Dickinson and Company)
Type	Public
Industry	Medical technology
Founded	1897
Founder	Phillip Becton; Maxwell Dickinson
Headquarters	Franklin Lakes, New Jersey, United States
Area served	Worldwide
Key people	Robert A. Dalton
Revenue	US$ 20+ billion (2023)
Num employees	~80,000

BD (Becton, Dickinson and Company) BD is a multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. Founded in the late 19th century, BD operates across clinical, pharmaceutical, and diagnostic markets with operations spanning North America, Europe, Asia, and Latin America. The company serves hospitals, research institutions, pharmaceutical firms, and public health agencies.

History

BD was founded in 1897 by Phillip Becton and Maxwell Dickinson in the context of industrializing Newark, New Jersey, during an era that included contemporaries such as Johnson & Johnson, Eli Lilly and Company, and Baxter International. Early growth paralleled developments at Rockefeller Institute and collaborations with hospitals like Massachusetts General Hospital and Johns Hopkins Hospital. Throughout the 20th century BD expanded via acquisitions, integrating technologies from companies such as C.R. Bard, CareFusion, and Genetix. During the postwar period BD's trajectory intersected with regulatory shifts at the Food and Drug Administration and research advances at institutions including Harvard Medical School, Stanford University, and Karolinska Institutet. In recent decades BD engaged with global health initiatives coordinated by bodies like the World Health Organization, Centers for Disease Control and Prevention, and Gavi, the Vaccine Alliance.

Products and Services

BD's product portfolio includes medical devices such as syringes, needles, infusion catheters, and safety-engineered sharps used in settings from Mayo Clinic to community clinics supported by Médecins Sans Frontières. The company supplies diagnostic systems and reagents for laboratories, competing with firms including Roche, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific. BD also provides medication management and pharmaceutical systems used by Pfizer, Merck & Co., and hospital pharmacies at Cleveland Clinic and Kaiser Permanente. Instrumentation for molecular diagnostics relates to research at Broad Institute and Cold Spring Harbor Laboratory, while BD's products contribute to clinical trials run by organizations such as Pharmaceutical Research and Manufacturers of America and European Medicines Agency.

Corporate Governance and Leadership

BD's board and executive management have included leaders with backgrounds at corporations and institutions like General Electric, Procter & Gamble, Goldman Sachs, Bain & Company, Harvard Business School, and Wharton School. The company's governance framework aligns with listing requirements on the New York Stock Exchange and practices advocated by investor groups such as BlackRock, Vanguard Group, and State Street Corporation. Executive decisions have responded to shareholder actions by entities including Elliott Management Corporation and regulatory engagement with the Securities and Exchange Commission. BD’s leadership teams often interact with policy circles in Washington, D.C., industry consortia like AdvaMed, and international forums such as the World Economic Forum.

Research, Development, and Innovation

BD invests in R&D collaborating with academic partners such as University of Pennsylvania, University of California, San Francisco, Imperial College London, and ETH Zurich. Programmatic work spans diagnostics aligned with initiatives from Bill & Melinda Gates Foundation and technology partnerships with firms like Illumina and Agilent Technologies. Innovation pipelines address antimicrobial stewardship referenced by Centers for Disease Control and Prevention priority programs and precision medicine trends popularized by projects at NIH and Human Genome Project legacy centers. BD has pursued digital health integrations compatible with platforms from Cerner Corporation and Epic Systems Corporation.

Global Operations and Markets

BD operates manufacturing and distribution networks across regions including United States, Germany, China, India, Brazil, and Japan, supplying customers such as national health systems like the National Health Service (England), private hospital groups like HCA Healthcare, and public health agencies in partnership with Pan American Health Organization. Market competition involves multinational corporations Johnson & Johnson, Medtronic, Becton Dickinson-adjacent suppliers, and regional players in emerging markets such as Wipro-supported distributors in India and multinational logistics partners like FedEx and DHL for global supply chains.

Financial Performance

BD is publicly traded and reports revenues, operating income, and cash flow in quarterly filings to the Securities and Exchange Commission. Financial performance has been influenced by large-scale acquisitions such as the purchase of CareFusion and by market dynamics including demand spikes during public health events like the 2009 swine flu pandemic and the COVID-19 pandemic. Institutional investors and credit rating agencies including Moody's Investors Service, Standard & Poor's, and Fitch Ratings monitor BD’s financial metrics and debt structure. The company’s earnings reports reference partnerships and contracts with pharmaceutical firms such as Johnson & Johnson, GlaxoSmithKline, and AstraZeneca.

Controversies and Legal Issues

BD has faced litigation and regulatory scrutiny related to product liability claims in court systems including the United States District Court and appellate courts, with cases sometimes involving plaintiffs represented alongside firms like Kirkland & Ellis or Skadden, Arps, Slate, Meagher & Flom. Antitrust concerns have arisen in contexts similar to actions involving Federal Trade Commission enforcement and merger reviews by the European Commission. BD has been involved in disputes over pricing and procurement in government contracting arenas such as procurements overseen by Department of Health and Human Services and procurement challenges in countries like Brazil and South Africa. The company has also addressed compliance programs responding to investigations by agencies including the Department of Justice and settled matters involving product recalls coordinated with the Food and Drug Administration.

Category:Medical technology companies